Skip to main content
Erschienen in: Oral and Maxillofacial Surgery 2/2023

09.04.2022 | Original Article

Significance of bisphosphonates on angiogenesis in vivo and their effect under geranyl-geraniol addition — could it alter the treatment of bisphosphonate-associated necrosis of the jaw?

verfasst von: Marius Otto, Julia Weigel, Thomas Ziebart, Juliana Lemound

Erschienen in: Oral and Maxillofacial Surgery | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to contribute to the understanding of the inhibitory effects of bisphosphonates on tissues, with a special focus on angiogenesis. Referring to bisphosphonate-associated osteonecrosis of the jaw (BP-ONJ), it should be shown that the local addition of the isoprenoid geranyl-geraniol (GGOH) prevents vascularization processes.

Methods

A mouse model with n = 24 animals which received an injection of a collagen matrix was used. In 4 subgroups (n = 6), we examined the effect of zoledronate on the sprouting of capillary-like structures into the matrix, with and without the presence of geranyl-geraniol, as well as testing against control groups with PBS injections or collagen matrix containing PBS instead of GGOH. This was followed by a histological evaluation of the capillary-like structures.

Results

Zoledronate inhibits the sprouting of blood vessels into a collagen matrix in vivo; in the presence of GGOH this effect is significantly weakened by a factor of 3.9 (p = 0.00068).

Conclusion

This work commits to the investigation of the pathophysiology of BP-ONJ and shows a possible causal therapeutic path via the topical application of GGOH.
Literatur
1.
Zurück zum Zitat Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61(9):1115–1117CrossRefPubMed Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61(9):1115–1117CrossRefPubMed
2.
Zurück zum Zitat Walter C, Grotz KA, Kunkel M, Al-Nawas B (2007) Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 15(2):197–202CrossRefPubMed Walter C, Grotz KA, Kunkel M, Al-Nawas B (2007) Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 15(2):197–202CrossRefPubMed
3.
Zurück zum Zitat Rugani P, Luschin G, Jakse N, Kirnbauer B, Lang U, Acham S (2014) Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer. Clin Oral Investig 18(2):401–407CrossRefPubMed Rugani P, Luschin G, Jakse N, Kirnbauer B, Lang U, Acham S (2014) Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer. Clin Oral Investig 18(2):401–407CrossRefPubMed
4.
6.
Zurück zum Zitat Hughes DE, MacDonald BR, Russell RG, Gowen M (1989) Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest. [Research Support, Non-U.S. Gov’t] 83(6):1930–5 Hughes DE, MacDonald BR, Russell RG, Gowen M (1989) Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest. [Research Support, Non-U.S. Gov’t] 83(6):1930–5
7.
Zurück zum Zitat Jobke B, Milovanovic P, Amling M, Busse B (2014) Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients. Bone. [Research Support, Non-U.S. Gov't] 59:37–43 Jobke B, Milovanovic P, Amling M, Busse B (2014) Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients. Bone. [Research Support, Non-U.S. Gov't] 59:37–43
8.
Zurück zum Zitat Pabst AM, Kruger M, Ziebart T, Jacobs C, Walter C (2015) Isoprenoid geranylgeraniol: the influence on cell characteristics of endothelial progenitor cells after bisphosphonate therapy in vitro. Clin Oral Investig. 19(7):1625–1633CrossRefPubMed Pabst AM, Kruger M, Ziebart T, Jacobs C, Walter C (2015) Isoprenoid geranylgeraniol: the influence on cell characteristics of endothelial progenitor cells after bisphosphonate therapy in vitro. Clin Oral Investig. 19(7):1625–1633CrossRefPubMed
9.
Zurück zum Zitat Hagelauer N, Ziebart T, Pabst AM, Walter C (2014) Bisphosphonates inhibit cell functions of HUVECs, fibroblasts and osteogenic cells via inhibition of protein geranylgeranylation. Clin Oral Investig. 19(5):1079–1091CrossRefPubMed Hagelauer N, Ziebart T, Pabst AM, Walter C (2014) Bisphosphonates inhibit cell functions of HUVECs, fibroblasts and osteogenic cells via inhibition of protein geranylgeranylation. Clin Oral Investig. 19(5):1079–1091CrossRefPubMed
10.
Zurück zum Zitat Koch FP, Yekta SS, Merkel C, Ziebart T, Smeets R (2010) The impact of bisphosphonates on the osteoblast proliferation and Collagen gene expression in vitro. Head Face Med. [Comparative Study In Vitro] 6:12 Koch FP, Yekta SS, Merkel C, Ziebart T, Smeets R (2010) The impact of bisphosphonates on the osteoblast proliferation and Collagen gene expression in vitro. Head Face Med. [Comparative Study In Vitro] 6:12
11.
Zurück zum Zitat Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart T (2010) Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig 14(1):35–41CrossRefPubMed Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart T (2010) Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig 14(1):35–41CrossRefPubMed
12.
Zurück zum Zitat Vassiliadou A (2003) Humane Osteoblasten und Bisphosphonate: eine in vitro Studie des Verhaltens von humanen Osteoblasten unter dem Einfluß von Bisphosphonaten verschiedener Generationen: Universitätsbibliothek Giessen Vassiliadou A (2003) Humane Osteoblasten und Bisphosphonate: eine in vitro Studie des Verhaltens von humanen Osteoblasten unter dem Einfluß von Bisphosphonaten verschiedener Generationen: Universitätsbibliothek Giessen
13.
Zurück zum Zitat Walter C, Pabst A, Ziebart T, Klein M, Al-Nawas B (2011) Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro. Oral Dis. [Comparative Study] 17(2):194–9 Walter C, Pabst A, Ziebart T, Klein M, Al-Nawas B (2011) Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro. Oral Dis. [Comparative Study] 17(2):194–9
14.
Zurück zum Zitat Ziebart T, Pabst A, Klein MO, Kammerer P, Gauss L, Brullmann D et al (2011) Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig 15(1):105–111CrossRefPubMed Ziebart T, Pabst A, Klein MO, Kammerer P, Gauss L, Brullmann D et al (2011) Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig 15(1):105–111CrossRefPubMed
15.
Zurück zum Zitat Koch FP, Wunsch A, Merkel C, Ziebart T, Pabst A, Yekta SS et al (2011) The influence of bisphosphonates on human osteoblast migration and integrin aVb3/tenascin C gene expression in vitro. Head Face Med. [In Vitro] 7(1):4 Koch FP, Wunsch A, Merkel C, Ziebart T, Pabst A, Yekta SS et al (2011) The influence of bisphosphonates on human osteoblast migration and integrin aVb3/tenascin C gene expression in vitro. Head Face Med. [In Vitro] 7(1):4
16.
Zurück zum Zitat Koch FP, Merkel C, Al-Nawas B, Smeets R, Ziebart T, Walter C et al (2011) Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner--a quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2. J Craniomaxillofac Surg. [Comparative Study] 39(8):562–9 Koch FP, Merkel C, Al-Nawas B, Smeets R, Ziebart T, Walter C et al (2011) Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner--a quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2. J Craniomaxillofac Surg. [Comparative Study] 39(8):562–9
17.
Zurück zum Zitat Koch FP, Merkel C, Ziebart T, Smeets R, Walter C, Al-Nawas B (2012) Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro. Clin Oral Investig. [Comparative Study] 16(1):79–86 Koch FP, Merkel C, Ziebart T, Smeets R, Walter C, Al-Nawas B (2012) Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro. Clin Oral Investig. [Comparative Study] 16(1):79–86
18.
Zurück zum Zitat Otto M, Lux C, Schlittenbauer T, Halling F, Ziebart T (2021) Geranyl-geraniol addition affects potency of bisphosphonates-a comparison in vitro promising a therapeutic approach for bisphosphonate-associated osteonecrosis of the jaw and oral wound healing. Oral Maxillofac Surg. https://doi.org/10.1007/s10006-021-00982-8 Otto M, Lux C, Schlittenbauer T, Halling F, Ziebart T (2021) Geranyl-geraniol addition affects potency of bisphosphonates-a comparison in vitro promising a therapeutic approach for bisphosphonate-associated osteonecrosis of the jaw and oral wound healing. Oral Maxillofac Surg. https://​doi.​org/​10.​1007/​s10006-021-00982-8
19.
Zurück zum Zitat Sasaki K, Heeschen C, Aicher A, Ziebart T, Honold J, Urbich C et al (2006) Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy. Proc Natl Acad Sci USA 103(39):14537–14541CrossRefPubMedPubMedCentral Sasaki K, Heeschen C, Aicher A, Ziebart T, Honold J, Urbich C et al (2006) Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy. Proc Natl Acad Sci USA 103(39):14537–14541CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Ziebart T, Yoon CH, Trepels T, Wietelmann A, Braun T, Kiessling F et al (2008) Sustained persistence of transplanted proangiogenic cells contributes to neovascularization and cardiac function after ischemia. Circ Res. [Research Support, Non-U.S. Gov't] 103(11):1327–34 Ziebart T, Yoon CH, Trepels T, Wietelmann A, Braun T, Kiessling F et al (2008) Sustained persistence of transplanted proangiogenic cells contributes to neovascularization and cardiac function after ischemia. Circ Res. [Research Support, Non-U.S. Gov't] 103(11):1327–34
21.
Zurück zum Zitat Konerding MA, Ziebart T, Wolloscheck T, Wellmann A, Ackermann M (2012) Impact of single-dose application of TGF-beta, copper peptide, stanozolol and ascorbic acid in hydrogel on midline laparatomy wound healing in a diabetic mouse model. Int J Mol Med 30(2):271–276CrossRefPubMed Konerding MA, Ziebart T, Wolloscheck T, Wellmann A, Ackermann M (2012) Impact of single-dose application of TGF-beta, copper peptide, stanozolol and ascorbic acid in hydrogel on midline laparatomy wound healing in a diabetic mouse model. Int J Mol Med 30(2):271–276CrossRefPubMed
22.
Zurück zum Zitat Liu GT, Huang YL, Tzeng HE, Tsai CH, Wang SW, Tang CH (2015) CCL5 promotes vascular endothelial growth factor expression and induces angiogenesis by down-regulating miR-199a in human chondrosarcoma cells. Cancer Lett 357(2):476–487CrossRefPubMed Liu GT, Huang YL, Tzeng HE, Tsai CH, Wang SW, Tang CH (2015) CCL5 promotes vascular endothelial growth factor expression and induces angiogenesis by down-regulating miR-199a in human chondrosarcoma cells. Cancer Lett 357(2):476–487CrossRefPubMed
23.
Zurück zum Zitat Ahmad S, Hewett PW, Fujisawa T, Sissaoui S, Cai M, Gueron G et al (2015) Carbon monoxide inhibits sprouting angiogenesis and vascular endothelial growth factor receptor-2 phosphorylation. Thromb Haemost 113(2):329–337CrossRefPubMed Ahmad S, Hewett PW, Fujisawa T, Sissaoui S, Cai M, Gueron G et al (2015) Carbon monoxide inhibits sprouting angiogenesis and vascular endothelial growth factor receptor-2 phosphorylation. Thromb Haemost 113(2):329–337CrossRefPubMed
24.
Zurück zum Zitat Petersen LC, Norby PL, Branner S, Sorensen BB, Elm T, Stennicke HR et al (2005) Characterization of recombinant murine factor VIIa and recombinant murine tissue factor: a human-murine species compatibility study. Thromb Res 116(1):75–85CrossRefPubMed Petersen LC, Norby PL, Branner S, Sorensen BB, Elm T, Stennicke HR et al (2005) Characterization of recombinant murine factor VIIa and recombinant murine tissue factor: a human-murine species compatibility study. Thromb Res 116(1):75–85CrossRefPubMed
25.
Zurück zum Zitat Ruggiero SL (2008) Bisphosphonate-related osteonecrosis of the jaws. Compend Contin Educ Dent 29(2):96–8, 100–2, 4–5 Ruggiero SL (2008) Bisphosphonate-related osteonecrosis of the jaws. Compend Contin Educ Dent 29(2):96–8, 100–2, 4–5
26.
Zurück zum Zitat Enjuanes A, Ruiz-Gaspa S, Peris P, Ozalla D, Alvarez L, Combalia A et al (2010) The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts. Endocrine 37(1):180–186CrossRefPubMed Enjuanes A, Ruiz-Gaspa S, Peris P, Ozalla D, Alvarez L, Combalia A et al (2010) The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts. Endocrine 37(1):180–186CrossRefPubMed
27.
Zurück zum Zitat Jin J, Wang L, Wang XK, Lai PL, Huang MJ, Jin DD et al (2013) Risedronate inhibits bone marrow mesenchymal stem cell adipogenesis and switches RANKL/OPG ratio to impair osteoclast differentiation. J Surg Res 180(1):e21–e29CrossRefPubMed Jin J, Wang L, Wang XK, Lai PL, Huang MJ, Jin DD et al (2013) Risedronate inhibits bone marrow mesenchymal stem cell adipogenesis and switches RANKL/OPG ratio to impair osteoclast differentiation. J Surg Res 180(1):e21–e29CrossRefPubMed
28.
Zurück zum Zitat Tsubaki M, Satou T, Itoh T, Imano M, Yanae M, Kato C et al (2012) Bisphosphonate- and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2. Mol Cell Endocrinol 361(1–2):219–231CrossRefPubMed Tsubaki M, Satou T, Itoh T, Imano M, Yanae M, Kato C et al (2012) Bisphosphonate- and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2. Mol Cell Endocrinol 361(1–2):219–231CrossRefPubMed
29.
Zurück zum Zitat Price N, Lipton A, Jain VK, Ruggiero S (2004) Prevention and management of osteonecrosis of the jaw associated with bisphosphonate therapy. Support Cancer Ther 2(1):14–17CrossRefPubMed Price N, Lipton A, Jain VK, Ruggiero S (2004) Prevention and management of osteonecrosis of the jaw associated with bisphosphonate therapy. Support Cancer Ther 2(1):14–17CrossRefPubMed
30.
Zurück zum Zitat Pabst AM, Ziebart T, Ackermann M, Konerding MA, Walter C (2014) Bisphosphonates’ antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in vivo 3D Matrigel assay. Clin Oral Investig 18(3):1015–1022CrossRefPubMed Pabst AM, Ziebart T, Ackermann M, Konerding MA, Walter C (2014) Bisphosphonates’ antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in vivo 3D Matrigel assay. Clin Oral Investig 18(3):1015–1022CrossRefPubMed
31.
Zurück zum Zitat Voss PJ, Stoddart MJ, Bernstein A, Schmelzeisen R, Nelson K, Stadelmann V et al (2016) Zoledronate induces bisphosphonate-related osteonecrosis of the jaw in osteopenic sheep. Clin Oral Invest 20(1):31–38CrossRef Voss PJ, Stoddart MJ, Bernstein A, Schmelzeisen R, Nelson K, Stadelmann V et al (2016) Zoledronate induces bisphosphonate-related osteonecrosis of the jaw in osteopenic sheep. Clin Oral Invest 20(1):31–38CrossRef
32.
Zurück zum Zitat Voss PJ, Stoddart M, Ziebart T, Zeiter S, Nelson K, Bittermann G et al (2015) Zoledronate induces osteonecrosis of the jaw in sheep. J Cranio-Maxillofac Surg 43(7):1133–1138CrossRef Voss PJ, Stoddart M, Ziebart T, Zeiter S, Nelson K, Bittermann G et al (2015) Zoledronate induces osteonecrosis of the jaw in sheep. J Cranio-Maxillofac Surg 43(7):1133–1138CrossRef
33.
Zurück zum Zitat Wehrhan F, Stockmann P, Nkenke E, Schlegel KA, Guentsch A, Wehrhan T et al (2011) Differential impairment of vascularization and angiogenesis in bisphosphonate-associated osteonecrosis of the jaw-related mucoperiosteal tissue. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112(2):216–221CrossRefPubMed Wehrhan F, Stockmann P, Nkenke E, Schlegel KA, Guentsch A, Wehrhan T et al (2011) Differential impairment of vascularization and angiogenesis in bisphosphonate-associated osteonecrosis of the jaw-related mucoperiosteal tissue. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112(2):216–221CrossRefPubMed
34.
Zurück zum Zitat Backman U, Svensson A, Christofferson RH, Azarbayjani F (2008) The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis. Anticancer Res 28(3A):1551–1557PubMed Backman U, Svensson A, Christofferson RH, Azarbayjani F (2008) The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis. Anticancer Res 28(3A):1551–1557PubMed
35.
Zurück zum Zitat Ledoux D, Hamma-Kourbali Y, Di Benedetto M, Foucault-Bertaud A, Oudar O, Sainte-Catherine O et al (2006) A new dimethyl ester bisphosphonate inhibits angiogenesis and growth of human epidermoid carcinoma xenograft in nude mice. Anticancer Drugs 17(4):479–485CrossRefPubMed Ledoux D, Hamma-Kourbali Y, Di Benedetto M, Foucault-Bertaud A, Oudar O, Sainte-Catherine O et al (2006) A new dimethyl ester bisphosphonate inhibits angiogenesis and growth of human epidermoid carcinoma xenograft in nude mice. Anticancer Drugs 17(4):479–485CrossRefPubMed
36.
Zurück zum Zitat Asahara T, Isner JM (2002) Endothelial progenitor cells for vascular regeneration. J Hematother Stem Cell Res 11(2):171–178CrossRefPubMed Asahara T, Isner JM (2002) Endothelial progenitor cells for vascular regeneration. J Hematother Stem Cell Res 11(2):171–178CrossRefPubMed
37.
Zurück zum Zitat Otto M, Blatt S, Pabst A, Mandic R, Schwarz J, Neff A et al (2019) Influence of buffy coat–derived putative endothelial progenitor cells on tumor growth and neovascularization in oral squamous cell carcinoma xenografts. Clin Oral Invest 23(10):3767–3775CrossRef Otto M, Blatt S, Pabst A, Mandic R, Schwarz J, Neff A et al (2019) Influence of buffy coat–derived putative endothelial progenitor cells on tumor growth and neovascularization in oral squamous cell carcinoma xenografts. Clin Oral Invest 23(10):3767–3775CrossRef
38.
Zurück zum Zitat Ziebart T, Schnell A, Walter C, Kammerer PW, Pabst A, Lehmann KM et al (2013) Interactions between endothelial progenitor cells (EPC) and titanium implant surfaces. Clin Oral Investig 17(1):301–309CrossRefPubMed Ziebart T, Schnell A, Walter C, Kammerer PW, Pabst A, Lehmann KM et al (2013) Interactions between endothelial progenitor cells (EPC) and titanium implant surfaces. Clin Oral Investig 17(1):301–309CrossRefPubMed
39.
Zurück zum Zitat Ziebart T, Ziebart J, Gauss L, Pabst A, Ackermann M, Smeets R et al (2013) Investigation of inhibitory effects on EPC-mediated neovascularization by different bisphosphonates for cancer therapy. Biomed Rep 1(5):719–722CrossRefPubMedPubMedCentral Ziebart T, Ziebart J, Gauss L, Pabst A, Ackermann M, Smeets R et al (2013) Investigation of inhibitory effects on EPC-mediated neovascularization by different bisphosphonates for cancer therapy. Biomed Rep 1(5):719–722CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Santini D, Zoccoli A, Gregorj C, Di Cerbo M, Iuliani M, Pantano F et al (2013) Zoledronic acid induces a significant decrease of circulating endothelial cells and circulating endothelial precursor cells in the early prostate cancer neoadjuvant setting. Oncology 85(6):342–347CrossRefPubMed Santini D, Zoccoli A, Gregorj C, Di Cerbo M, Iuliani M, Pantano F et al (2013) Zoledronic acid induces a significant decrease of circulating endothelial cells and circulating endothelial precursor cells in the early prostate cancer neoadjuvant setting. Oncology 85(6):342–347CrossRefPubMed
41.
Zurück zum Zitat Ahn JB, Rha SY, Shin SJ, Jeung HC, Kim TS, Zhang X et al (2010) Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients. Cancer Lett 288(1):124–132CrossRefPubMed Ahn JB, Rha SY, Shin SJ, Jeung HC, Kim TS, Zhang X et al (2010) Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients. Cancer Lett 288(1):124–132CrossRefPubMed
42.
Zurück zum Zitat Hilbe W, Dirnhofer S, Oberwasserlechner F, Schmid T, Gunsilius E, Hilbe G et al (2004) CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol 57(9):965–969CrossRefPubMedPubMedCentral Hilbe W, Dirnhofer S, Oberwasserlechner F, Schmid T, Gunsilius E, Hilbe G et al (2004) CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol 57(9):965–969CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Ackermann M, Pabst AM, Houdek JP, Ziebart T, Konerding MA (2014) Priming with proangiogenic growth factors and endothelial progenitor cells improves revascularization in linear diabetic wounds. Int J Mol Med 33(4):833–839CrossRefPubMedPubMedCentral Ackermann M, Pabst AM, Houdek JP, Ziebart T, Konerding MA (2014) Priming with proangiogenic growth factors and endothelial progenitor cells improves revascularization in linear diabetic wounds. Int J Mol Med 33(4):833–839CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Senel FC, Saracoglu Tekin U, Durmus A, Bagis B (2007) Severe osteomyelitis of the mandible associated with the use of non-nitrogen-containing bisphosphonate (disodium clodronate): report of a case. J Oral Maxillofac Surg 65(3):562–565CrossRefPubMed Senel FC, Saracoglu Tekin U, Durmus A, Bagis B (2007) Severe osteomyelitis of the mandible associated with the use of non-nitrogen-containing bisphosphonate (disodium clodronate): report of a case. J Oral Maxillofac Surg 65(3):562–565CrossRefPubMed
45.
Zurück zum Zitat Li H, Wang D, Li S, Liu B, Gao L (2004) Sustained release of BSA from a novel drug delivery matrix – bullfrog skin collagen film. Macromol Biosci 4(4):454–457CrossRefPubMed Li H, Wang D, Li S, Liu B, Gao L (2004) Sustained release of BSA from a novel drug delivery matrix – bullfrog skin collagen film. Macromol Biosci 4(4):454–457CrossRefPubMed
46.
Zurück zum Zitat Losic D, Cole MA, Dollmann B, Vasilev K, Griesser HJ (2008) Surface modification of nanoporous alumina membranes by plasma polymerization. Nanotechnology. 19(24):245704CrossRefPubMed Losic D, Cole MA, Dollmann B, Vasilev K, Griesser HJ (2008) Surface modification of nanoporous alumina membranes by plasma polymerization. Nanotechnology. 19(24):245704CrossRefPubMed
47.
Zurück zum Zitat Rump ET, de Vrueh RL, Manoharan M, Waarlo IH, van Veghel R, Biessen EA et al (2000) Modification of the plasma clearance and liver uptake of steroid ester-conjugated oligodeoxynucleotides by association with (lactosylated) low-density lipoprotein. Biochem Pharmacol 59(11):1407–1416CrossRefPubMed Rump ET, de Vrueh RL, Manoharan M, Waarlo IH, van Veghel R, Biessen EA et al (2000) Modification of the plasma clearance and liver uptake of steroid ester-conjugated oligodeoxynucleotides by association with (lactosylated) low-density lipoprotein. Biochem Pharmacol 59(11):1407–1416CrossRefPubMed
48.
Zurück zum Zitat Pietrucha K, Kroh J, Antczak J, Zakrzewski S, Rakowski W (1988) Use of low-temperature plasma in the preparation of synthetic polymers for modification by collagen. Polim Med 18(1–2):51–65PubMed Pietrucha K, Kroh J, Antczak J, Zakrzewski S, Rakowski W (1988) Use of low-temperature plasma in the preparation of synthetic polymers for modification by collagen. Polim Med 18(1–2):51–65PubMed
Metadaten
Titel
Significance of bisphosphonates on angiogenesis in vivo and their effect under geranyl-geraniol addition — could it alter the treatment of bisphosphonate-associated necrosis of the jaw?
verfasst von
Marius Otto
Julia Weigel
Thomas Ziebart
Juliana Lemound
Publikationsdatum
09.04.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Oral and Maxillofacial Surgery / Ausgabe 2/2023
Print ISSN: 1865-1550
Elektronische ISSN: 1865-1569
DOI
https://doi.org/10.1007/s10006-022-01053-2

Weitere Artikel der Ausgabe 2/2023

Oral and Maxillofacial Surgery 2/2023 Zur Ausgabe

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.